肿瘤专家对巴勒斯坦二氢嘧啶脱氢酶检测的看法和见解

IF 1.5 Q4 ONCOLOGY
Cancer reports Pub Date : 2025-06-24 DOI:10.1002/cnr2.70251
Mohammad Dweib, Hussein Hallak, Hani Hour, Asmahan Alzeer, Raya Fatafta, Leen Albaw
{"title":"肿瘤专家对巴勒斯坦二氢嘧啶脱氢酶检测的看法和见解","authors":"Mohammad Dweib,&nbsp;Hussein Hallak,&nbsp;Hani Hour,&nbsp;Asmahan Alzeer,&nbsp;Raya Fatafta,&nbsp;Leen Albaw","doi":"10.1002/cnr2.70251","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>This study aimed to assess the knowledge and opinions of HCPsspecializing in oncology in Palestine regarding screening for DPYD testing prior to prescribing FP.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A cross-sectional survey was distributed to 106 HCPs across various hospitals in Palestine.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A notable deficiency in training and implementation of pharmacogenomics was observed, with over 70% of participants lacking formal training in the field. Although there is high awareness of DPD deficiency and its impact, fewer than 50% of participants screen for DPD deficiency prior to prescribing fluoropyrimidines (FP). Standardization and promotion of DPD testing are low, and guidelines for prescribing FP are lacking, leading to variations in clinical practice.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These findings highlight the need for enhanced training, standardized protocols, and increased awareness to improve patient safety and outcomes in cancer treatment in Palestine.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 6","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70251","citationCount":"0","resultStr":"{\"title\":\"Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine\",\"authors\":\"Mohammad Dweib,&nbsp;Hussein Hallak,&nbsp;Hani Hour,&nbsp;Asmahan Alzeer,&nbsp;Raya Fatafta,&nbsp;Leen Albaw\",\"doi\":\"10.1002/cnr2.70251\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>This study aimed to assess the knowledge and opinions of HCPsspecializing in oncology in Palestine regarding screening for DPYD testing prior to prescribing FP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>A cross-sectional survey was distributed to 106 HCPs across various hospitals in Palestine.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A notable deficiency in training and implementation of pharmacogenomics was observed, with over 70% of participants lacking formal training in the field. Although there is high awareness of DPD deficiency and its impact, fewer than 50% of participants screen for DPD deficiency prior to prescribing fluoropyrimidines (FP). Standardization and promotion of DPD testing are low, and guidelines for prescribing FP are lacking, leading to variations in clinical practice.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>These findings highlight the need for enhanced training, standardized protocols, and increased awareness to improve patient safety and outcomes in cancer treatment in Palestine.</p>\\n </section>\\n </div>\",\"PeriodicalId\":9440,\"journal\":{\"name\":\"Cancer reports\",\"volume\":\"8 6\",\"pages\":\"\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cnr2.70251\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70251\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70251","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本研究评估了在巴勒斯坦医院工作的肿瘤学家、居民和临床药剂师对二氢嘧啶脱氢酶(DPD)检测和药物基因组学的认识、流行和利用情况。目的本研究旨在评估巴勒斯坦肿瘤学专业的hcps在处方FP之前进行DPYD筛查的知识和意见。方法对巴勒斯坦各医院106名医护人员进行横断面调查。结果在药物基因组学的培训和实施方面存在明显不足,超过70%的参与者缺乏该领域的正式培训。尽管人们对DPD缺乏症及其影响有很高的认识,但在处方氟嘧啶(FP)之前,只有不到50%的参与者筛查DPD缺乏症。DPD检测的标准化和推广程度较低,缺乏FP处方指南,导致临床实践存在差异。这些发现强调了加强培训、标准化方案和提高认识的必要性,以改善巴勒斯坦癌症治疗的患者安全和结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine

Background

This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals.

Aim

This study aimed to assess the knowledge and opinions of HCPsspecializing in oncology in Palestine regarding screening for DPYD testing prior to prescribing FP.

Methods

A cross-sectional survey was distributed to 106 HCPs across various hospitals in Palestine.

Results

A notable deficiency in training and implementation of pharmacogenomics was observed, with over 70% of participants lacking formal training in the field. Although there is high awareness of DPD deficiency and its impact, fewer than 50% of participants screen for DPD deficiency prior to prescribing fluoropyrimidines (FP). Standardization and promotion of DPD testing are low, and guidelines for prescribing FP are lacking, leading to variations in clinical practice.

Conclusion

These findings highlight the need for enhanced training, standardized protocols, and increased awareness to improve patient safety and outcomes in cancer treatment in Palestine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer reports
Cancer reports Medicine-Oncology
CiteScore
2.70
自引率
5.90%
发文量
160
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信